Sentences with phrase «treatment outcome of the disease»

UCLA scientists have unlocked an important mechanism that allows chemotherapy - carrying nanoparticles — extremely small objects between 1 and 100 nanometers (a billionth of a meter)-- to directly access pancreatic cancer tumors, thereby improving the ability to kill cancer cells and hence leading to more effective treatment outcome of the disease.

Not exact matches

But they've been hampered by somewhat skeptical physicians who still aren't sure that the drugs are worth their price (their topline costs are around $ 14,000 per treatment course); part of the problem is that it's unclear whether or not those dramatic cholesterol reductions actually translate into broader health outcomes like a reduced risk of stroke or heart attack in heart disease patients.

They are now examining some of the outpatient factors that may result in disparities, such as frequency of follow - up, and further investigating racial and socioeconomic disparities in treatment and outcomes of children with Crohn's disease.

«Our findings underscored the underutilization of this treatment modality in patients with this disease and identify an opportunity to better educate patients and physicians about improvements in surgical outcomes.»

Using data from the Pediatric Health Information System database, a large, regionally diverse system, the researchers examined racial disparities in the treatment and outcomes of hospitalized white and black pediatric patients with moderate to severe Crohn's disease.

Their findings could potentially enhance diagnosis of the disease and prediction of therapy outcomes for improved treatment successes.

As ICREA Prof. at ICFO Valerio Pruneri comments «the device means a major step forward for light microscopy techniques, especially for microarray platforms since it could definitely be used as a point - of - care tool in the diagnosis and treatment of major diseases such as Sepsis, a critical area where fast and accurate results can translate into life changing health outcomes for individuals.

Researchers from Massachusetts Eye and Ear / Harvard Medical School have found that patients who were prescribed corticosteroids as part of treatment for Lyme disease - associated facial paralysis had worse long - term outcomes of regaining facial function than those who were prescribed antibiotic therapy alone.

The authors suggest minimal residual disease status may be a marker of long - term survival outcome and the assessment of minimal residual disease status after treatment should be considered as an end - point in clinical trials.

While the treatment did have some favorable effects, in the main measure of outcome — measured with a cognitive test called the Alzheimer's Disease Assessment Scale - cognitive subscale — the researchers did not observe any statistically significant benefit compared with placebo.

«Since several BACE1 inhibitors are currently being evaluated in clinical phase 3 trials for the treatment of Alzheimer's disease, the identification of potential side effects will be of great importance to ensure a positive clinical outcome,» said Dr. Jochen Herms, a Professor of translational brain research at Ludwig - Maximilians - University Munich.

They also summarise the outcome of clinical trials that have investigated the use of mesenchymal stem cells in the treatment of a number of inflammatory, degenerative and immune - mediated diseases of cats.

«A better understanding of individual susceptibility to dental disease and variation in treatment outcomes will allow the dental field to move forward,» says Alexandre Vieira, a researcher involved in the study.

The control of excess weight, especially through lifestyle interventions, should be mandatory not only for improving reproductive and obstetric outcomes, but also for reducing costs derived from the greater consumption of drugs in IVF, failed treatments, maternal and neonatal complications, and metabolic and non-metabolic diseases in the offspring.»

In a survey to assess treatment preferences for high blood pressure, respondents were more likely to choose a daily cup of tea or a pill over exercise, according to preliminary research presented at the American Heart Association's Quality of Care and Outcomes Research Scientific Sessions 2018, a premier global exchange of the latest advances in quality of care and outcomes research in cardiovascular disease and stroke for researchers, healthcare professionals and policOutcomes Research Scientific Sessions 2018, a premier global exchange of the latest advances in quality of care and outcomes research in cardiovascular disease and stroke for researchers, healthcare professionals and policoutcomes research in cardiovascular disease and stroke for researchers, healthcare professionals and policymakers.

Tryfonidis et al. discuss perspectives and future directions for the management of locally advanced breast cancer in Nature Reviews Clinical Oncology, and they see a need for not only standardizing treatment for this disease, but also for developing new therapies that could substantially improve outcome.

The study is investigator led and has therefore focused on clinical need, targeting patients with progressive multiple sclerosis in whom most disability is incurred... The study also reports a predominant effect on neurodegenerative rather than inflammatory outcomes, suggesting a novel mechanism of action that might be suitable as combination treatment with immunomodulatory treatments... Further phase 3 studies to measure the effect of simvastatin on sustained disability, particularly in patients with non-relapsing secondary progressive and primary progressive multiple sclerosis, are clearly needed, but this trial represents a promising point from which to develop trials of progressive disease.»

The Chinese team has now applied this approach to understanding the spread of disease and demonstrated that there are four main outcomes one might see with a pandemic in today's world all affected by the government response to the outbreak, the provision of healthcare, the isolation of patients and availability of treatments of the given disease.

Their outcomes ultimately say nothing about the treatment: The people received the drug at different stages of disease, and four were evacuated to wealthy countries for top - notch care — likely the most important determinant of survival.

«This study allowed us to look more closely at the long - term outcomes of patients in whom the localized cancer in the prostate was successfully eradicated and compare them to patients whose disease persisted within the prostate following treatment,» adds Dr. Krauss.

As to the reason why certain racial and ethnic minorities have poorer rates of treatment for cardiovascular disease and generally have poorer cardiovascular health outcomes compared to white patients, Dr. Ladapo concludes that no one has really explored whether there could be disparities in cardiac stress testing, which is a mainstay of diagnosing patients with heart disease in this country.

The team is currently pursuing further studies of the impact of Part D cost - sharing policies in different disease areas, and hopes ultimately to get a better understanding not only of changes in drug access but also of the long range clinical outcomes and costs associated with any delays or interruptions in treatment.

Analysis of Treatment Outcomes for Recurrent Clostridium difficile Infections and Fecal Microbiota Transplantation in a Pediatric Hospital — Aileen Aldrich — The Pediatric Infectious Disease Journal

The hope, says Steere, is that this growing understanding of Lyme disease may lead to breakthroughs in treatment, and in heading off the worst outcomes.

«PROs supplement clinical outcomes and provide a holistic understanding of patient experience and treatment effectiveness, and help inform therapeutic choices, disease management practices, reimbursement decisions, and health policy,» said Dirk Schadendorf, MD, director of the department of dermatology at the University Hospital Essen in Essen, Germany.

Finally, we know that treatment early in the disease course is associated with improved efficacy of drugs and better outcomes, such as reduced risk for surgery.

Using a rapid learning approach, the goal of M2Gen is to accelerate the science of precision medicine by creating evidence and knowledge - based solutions that identify a patient's susceptibility to disease, predict how the patient will respond to a particular drug, and match patients to the best therapies for an optimal treatment outcome.

We also performed subgroup meta - analyses by type of prevention (primary v secondary: in this study, trials involving healthy populations or patients with any specific disease except for cardiovascular disease were classified as primary prevention trials, and trials involving patients with cardiovascular disease were classified as secondary prevention trials), type of supplement by quality and dose (each supplement, vitamins only, antioxidants only, or antioxidants excluding vitamins), type of outcome (cardiovascular death, angina, fatal or non-fatal myocardial infarction, stroke, or transient ischaemic attack), type of outcome in each supplement, type of study design (randomised, double blind, placebo controlled trial v open label, randomised controlled trial), methodological quality (high v low), duration of treatment (< 5 years v ≥ 5 years), funding source (pharmaceutical industry v independent organisation), provider of supplements (pharmaceutical industry v not pharmaceutical industry), type of control (placebo v no placebo), number of participants (≥ 10000 v < 10000), and supplements given singly or in combination with other vitamin or antioxidant supplements by quality.

Opportunities lie ahead in the creation of strong partnerships with patients to collect post-approval, real - world data on treatment outcomes, and in the use of patient - led registries to both cut drug development costs and generate data on disease history / treatment outcomes.

Introduction: The level of minimal residual disease (MRD) in marrow predicts outcome and guides treatment in childhood acute lymphoblastic leukemia (ALL) but accurate prediction depends on accurate measurement.

Immunochemotherapy and rituximab maintenance have improved patient outcomes in recent years, but 20 % of patients will see disease progression within 2 years of their initial treatment, according to the data.

This segment focuses on known disease state sample vs treatment outcome or normal samples and cohort sizes of 50 - 100 range.

Acute myeloid leukemia (AML) is the leading cause of leukemia mortality in the United States.1 Curative treatment involves intensive induction chemotherapy, before proceeding to either consolidation chemotherapy or allogeneic stem cell transplantation based on the patient's risk for relapse.2 This approach has been employed for > 4 decades and, although most individuals achieve complete remissions with front - line therapy, 3 the majority of patients ultimately relapse with drug - resistant disease, and overall survival rates remain disappointingly poor.4 The limited ability of many patients to tolerate the intense chemotherapy - based treatments, in particular hematological toxicity, further contributes to the poor outcomes noted in this disease.

Breast cancer is a heterogeneous disease with a high degree of diversity in histology, therapeutic response, and treatment outcomes.

However, far from encouraging people to consume unhealthy fats, this promising outcome may result in new therapeutic uses of Incas» peanut for the treatment of both hypertriglyceridemia and type 2 diabetes, as well as in new ways of preventing cardiovascular and metabolic diseases.

«We focus on metabolic - based research outcomes and mechanisms that advance the treatment and prevention of disease»

Treatment in Dogs: The extent of the preadulticide evaluation will vary depending on the clinical status of the patient and the likelihood of coexisting diseases that may affect the outcome of tTreatment in Dogs: The extent of the preadulticide evaluation will vary depending on the clinical status of the patient and the likelihood of coexisting diseases that may affect the outcome of treatmenttreatment.

Early detection of a disease process equates to early treatment and potentially a more favorable outcome or correction of a disease process.

The diagnosis and treatment of animals is a critical part of our job, but we must explain disease, treatments, and possible outcomes as they affect you, the owner.

Beyond diagnosis and treatment of animals we want to explain disease, preventative measures, treatments and possible outcomes to you as an owner.

We have found that early detection of diseases makes for better treatment outcomes.

Steroid responsive meningitis - arteritis: a prospective study of potential disease markers, prednisolone treatment, and long - term outcome in 20 dogs (2006 - 2008).

As with people, a combination of approaches may be used, and the stage of the cancer, the type of disease, and the aggressiveness of the treatment can affect the outcome.

The goal of treatment is to prevent or reduce the outcome of the disease.

Each stage is associated with a specific treatment protocol or plan and indicates a dog's prognosis (course and outcome of the disease).

• Your pet's disease is uncommon, complicated, or undiagnosed after standard testing • You would like an informed, neutral second opinion of your pet's condition • The outcomes of the current treatments are not going well or as expected • Your pet requires a sophisticated procedure that is offered only by a specialty hospital • Your pet can benefit from 24 - hour monitoring provided by a referral hospital

Knowing what is «normal» for your pet helps us to detect changes earlier which can lead to earlier diagnosis of disease, with more successful treatment outcomes.

Clinical trials represent the cutting edge of medicine: research expertise meets new treatments and improved outcomes, including an improved understanding of the diseases, like cancer, that affect our animals.

Such dramatic improvement in treatment outcomes means patients with a history of serious illness may qualify for standard life insurance rates — the same rates paid by people without pre-existing conditions — once their disease is under control.

Among the 16 Flexible Funds apparently to be affected are those supporting the provision of essential services in rural, regional and remote Australia; working to Close the Gap in health outcomes for Indigenous Australians; managing vital responses to communicable diseases; and delivering substance use treatment services around the country.